These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 21078393

  • 1. Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.
    Masuyer G, Beard M, Cadd VA, Chaddock JA, Acharya KR.
    J Struct Biol; 2011 Apr; 174(1):52-7. PubMed ID: 21078393
    [Abstract] [Full Text] [Related]

  • 2. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
    Arndt JW, Chai Q, Christian T, Stevens RC.
    Biochemistry; 2006 Mar 14; 45(10):3255-62. PubMed ID: 16519520
    [Abstract] [Full Text] [Related]

  • 3. Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors.
    Masuyer G, Davies JR, Moore K, Chaddock JA, Ravi Acharya K.
    Sci Rep; 2015 Sep 01; 5():13397. PubMed ID: 26324071
    [Abstract] [Full Text] [Related]

  • 4. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation.
    Kumaran D, Eswaramoorthy S, Furey W, Navaza J, Sax M, Swaminathan S.
    J Mol Biol; 2009 Feb 13; 386(1):233-45. PubMed ID: 19118561
    [Abstract] [Full Text] [Related]

  • 5. Structures of engineered Clostridium botulinum neurotoxin derivatives.
    Masuyer G, Stancombe P, Chaddock JA, Acharya KR.
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Dec 01; 67(Pt 12):1466-72. PubMed ID: 22139146
    [Abstract] [Full Text] [Related]

  • 6. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
    Wang J, Zurawski TH, Bodeker MO, Meng J, Boddul S, Aoki KR, Dolly JO.
    Biochem J; 2012 May 15; 444(1):59-67. PubMed ID: 22360156
    [Abstract] [Full Text] [Related]

  • 7. Identification of the amino acid residues rendering TI-VAMP insensitive toward botulinum neurotoxin B.
    Sikorra S, Henke T, Swaminathan S, Galli T, Binz T.
    J Mol Biol; 2006 Mar 24; 357(2):574-82. PubMed ID: 16430921
    [Abstract] [Full Text] [Related]

  • 8. Identification and characterization of a novel botulinum neurotoxin.
    Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L, Miyashita SI, Martínez-Carranza M, Dong M, Stenmark P.
    Nat Commun; 2017 Aug 03; 8():14130. PubMed ID: 28770820
    [Abstract] [Full Text] [Related]

  • 9. Molecular mechanisms of substrate recognition and specificity of botulinum neurotoxin serotype F.
    Chen S, Wan HY.
    Biochem J; 2011 Jan 15; 433(2):277-84. PubMed ID: 21029044
    [Abstract] [Full Text] [Related]

  • 10. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin.
    Shone CC, Roberts AK.
    Eur J Biochem; 1994 Oct 01; 225(1):263-70. PubMed ID: 7925446
    [Abstract] [Full Text] [Related]

  • 11. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.
    Jin R, Rummel A, Binz T, Brunger AT.
    Nature; 2006 Dec 21; 444(7122):1092-5. PubMed ID: 17167421
    [Abstract] [Full Text] [Related]

  • 12. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.
    Hanson MA, Stevens RC.
    Nat Struct Biol; 2000 Aug 21; 7(8):687-92. PubMed ID: 10932255
    [Abstract] [Full Text] [Related]

  • 13. Molecular structures and functional relationships in clostridial neurotoxins.
    Swaminathan S.
    FEBS J; 2011 Dec 21; 278(23):4467-85. PubMed ID: 21592305
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Specificity of botulinum protease for human VAMP family proteins.
    Yamamoto H, Ida T, Tsutsuki H, Mori M, Matsumoto T, Kohda T, Mukamoto M, Goshima N, Kozaki S, Ihara H.
    Microbiol Immunol; 2012 Apr 21; 56(4):245-53. PubMed ID: 22289120
    [Abstract] [Full Text] [Related]

  • 16. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
    Zhou Y, Singh BR.
    Protein Expr Purif; 2004 Mar 21; 34(1):8-16. PubMed ID: 14766296
    [Abstract] [Full Text] [Related]

  • 17. [Mechanisms of action of botulinum toxins and neurotoxins].
    Poulain B, Lonchamp E, Jover E, Popoff MR, Molgó J.
    Ann Dermatol Venereol; 2009 May 21; 136 Suppl 4():S73-6. PubMed ID: 19576489
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the substrate recognition domain determinants of botulinum type B toxin using phage display.
    Evans ER, Sutton JM, Gravett A, Shone CC.
    Toxicon; 2005 Sep 15; 46(4):446-53. PubMed ID: 16112699
    [Abstract] [Full Text] [Related]

  • 19. Structural basis of cell surface receptor recognition by botulinum neurotoxin B.
    Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapman ER, Stevens RC.
    Nature; 2006 Dec 21; 444(7122):1096-100. PubMed ID: 17167418
    [Abstract] [Full Text] [Related]

  • 20. Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes.
    Baldwin MR, Barbieri JT.
    Biochemistry; 2007 Mar 20; 46(11):3200-10. PubMed ID: 17311420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.